Search - tctmd.com

Displaying 61 - 80 of 14760

Sort: Relevancy | Date

News Daily News

Recognize and Enable Care for Post-MI Psychological Distress: AHA

L.A. McKeown

October 01, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

Lactate Clearance May Act as ‘Early Warning Sign’ in Cardiogenic Shock

L.A. McKeown

September 25, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

News Daily News

European Experts Provide Advice on Managing CV Effects of COVID-19

Todd Neale

September 19, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Features

‘Buzz and Discussion’ Driving Return to In-Person Cardiology Meetings

Michael O'Riordan

September 17, 2025

News Daily News

Nonatherosclerotic Causes of MI Common in Younger Patients

L.A. McKeown

September 17, 2025

News Industry News

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

September 15, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

L.A. McKeown

September 09, 2025

News Conference News ESC 2025

DanGer Shock: Impella Tied to Better Survival Even 10 Years Later

Caitlin E. Cox

September 08, 2025

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

Caitlin E. Cox

September 05, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

Presentation ESC 2025

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

Presenter: David Newby

September 03, 2025

News Conference News ESC 2025

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Todd Neale

September 03, 2025

Presentation ESC 2025

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Presenter: Subodh Verma

September 01, 2025

Presentation ESC 2025

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

Presenter: Anders Jeppsson

September 01, 2025

Advertisement

Recognize and Enable Care for Post-MI Psychological Distress: AHA

TCTMD’s Top 10 Most Popular Stories for September 2025

September 2025 Dispatch for the CV Team

Lactate Clearance May Act as ‘Early Warning Sign’ in Cardiogenic Shock

CVD Still the Leading Cause of Death and Disease Globally

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

European Experts Provide Advice on Managing CV Effects of COVID-19

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

‘Buzz and Discussion’ Driving Return to In-Person Cardiology Meetings

Nonatherosclerotic Causes of MI Common in Younger Patients

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

DanGer Shock: Impella Tied to Better Survival Even 10 Years Later

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial

HELP-MI SWEDEHEART: Routine H. Pylori Screening Doesn’t Lessen Bleeding After MI

Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial

Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content